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atypical antipsychotics (olanzapine, risperidone, quetiapine, and
ziprasidone) using different deﬁnitions of persistence and data-
cutting criteria to assess their impact on the results and conclu-
sions. METHODS: Using the Pennsylvania Medicaid database
(January 1999–June 2003), patients diagnosed with schizophre-
nia, aged 18–64 who initiated an antipsychotic of interest after
a 3-month period without the index drug were identiﬁed. A treat-
ment episode was deﬁned as the period from the initiation date
of index medication to the ﬁrst medication gap. To assess the
effect of methodological changes on study outcomes three
methodologies were implemented: 1) 30- vs. 90-day gap to deﬁne
treatment discontinuation; 2) multi-episode vs. ﬁrst- or last-
episod; and 3) 1-year ﬁxed study duration. RESULTS: Using a
30-day gap to deﬁne treatment discontinuation, 43,491 treat-
ment episodes were identiﬁed (olanzapine = 16,709, risperidone
= 14,847, quetiapine = 8648, ziprasidone = 3287) for 24,365
patients. Average duration of these episodes was 211, 197, 180,
130 days, respectively for olanzapine, risperidone, quetiapine,
and ziprasidone and increased to 253, 236, 201, and 144 days
respectively using the last episode approach. Imposing a ﬁxed 1-
year study duration effectively truncated the longer treatment
episodes and had a different impact on the persistence of olan-
zapine (190 days), risperidone (183 days), quetiapine (170 days),
and ziprasidone (143 days). Similar patterns were observed using
a 90-day gap criteria. CONCLUSION: In claims database
studies, the approaches used to deﬁne persistence and treatment
episodes affect the persistence of individual medications and may
impact the outcomes and conclusions of a persistence study. It is
critical, therefore, to carefully consider the analysis criteria and
the use of sensitivity analysis with multiple data-cutting scenar-
ios in order to provide a better understanding of the data.
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OBJECTIVES: To develop a stochastic multi-domain micro-
simulation model for evaluation of cost-effectiveness and long-
term outcome in Alzheimer’s disease. METHODS: Key disease
indicators (e.g. cognitive function, functional abilities—ADLs
and care setting) were simulated over time for individual patients
using regression functions derived from longitudinal observa-
tional data. Micro-simulation of each individual patient enables
incorporating individual variability over time into the model, i.e.
the disease progression depends on individual characteristics and
previous progression rates. The disease indicators together with
patient characteristics were used to predict the need for health
care services and ultimately the need for full time care.
RESULTS: The model simulated individual patients estimating
cognitive function, physical function, resource utilization and
care setting for each 6 months period until the event of death.
Average disease progression rates and estimated resource use
well corresponded to what have been observed in clinical praxis.
CONCLUSION: Existing models stratify patients into artiﬁcial
cohorts using single domains (typically either cognition or care
setting) thereby neglecting important explanatory variables and
limiting the extent to which individual variability can be
modeled. The proposed model provides a dynamic simulation
framework completely based on regression functions. This
enables inclusion of all relevant disease indicators and incorpo-
ration of individual variability into disease progression func-
tions. The proposed model can be used for economic evaluation
of any treatment intervention.
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OBJECTIVES: To compare 12-month outcomes in patients with
schizophrenia who received risperidone long-acting injectable
(RLAI) treatment and are enrolled in the electronic-Schizophre-
nia Treatment Adherence Registry (e-STAR) in Spain (SP), Aus-
tralia (AU), and Belgium (BE). METHODS: E-STAR is a secure,
web-based, international, long-term observational study of
patients with schizophrenia who commence RLAI treatment.
Data are collected both retrospectively and prospectively. Reason
for initiating RLAI and treatment discontinuation data were col-
lected. RESULTS: A total of 2498 patients (SP = 1332, AU =
763, BE = 403) were included in this analysis. At 12-months,
84% (CI = 81.5–86.2), 52.2% (CI = 48.2–56.0), and 71.6% (CI
= 65.3–77.1) of patients in Spain, Australia and Belgium were
still being maintained on RLAI respectively. The three most
common reasons reported for discontinuing RLAI was “insufﬁ-
cient response”, “choice”, and “lost to follow-up”. The most
important reason reported for initiating RLAI was “compliance”
in Australia and Belgium (AU = 52%, BE = 43%). In Spain it
was “insufﬁcient response” (33%) followed closely by compli-
ance (32%). The differences seen in the results may partially be
due to differences in the baseline characteristics of the patients.
The age of patients at baseline was signiﬁcantly different (SP =
38.3, AU = 37.1, BE = 39.9; p = 0.0005). Time since diagnosis
(in years) was signiﬁcantly higher in Spain than Australia and
Belgium (SP = 12.6, AU = 10.6, BE = 9.3; p < 0.0001). Spanish
patients had signiﬁcantly higher baseline GAF scores than the
Australian and Belgian patients (SP = 46.8, AU = 42.6, BE = 44;
p < 0.0001). The proportion of inpatients was signiﬁcantly dif-
ferent between the three countries (SP = 9.2%, AU = 51.6%, BE
= 55.6%; p < 0.0001). Finally, the proportion of patients
employed (full-time and part-time) was also signiﬁcantly differ-
ent (SP = 12.7%, AU = 8.5%, BE = 15.4%; p < 0.0008). Due to
these differences, data were not pooled. CONCLUSION: This
interim analysis shows that the majority of patients were still
maintained on RLAI at 12-months. However, the discontinua-
tion rates of RLAI were signiﬁcantly different between countries.
This may partially be due to differing baseline patient charac-
teristics in the countries.
